Carpal Tunnel Hydrodissection: What the 2026 Trials Found

In October 2026, a randomized trial published in Radiology reported that a 15-minute, ultrasound-guided procedure using plain salt water — no steroid at all — eased stubborn carpal tunnel symptoms for at least six months. A second 2026 trial, in Muscle & Nerve, found a sugar-water injection matched a steroid over a full year. Neither study is a reason to book a procedure tomorrow. Together, they are the most interesting shift in carpal tunnel care in years.

What hydrodissection actually is

Carpal tunnel syndrome happens when the median nerve is squeezed inside the narrow passage at the wrist. The standard non-surgical steps are familiar to readers of this site: a night splint to keep the wrist straight, activity changes, and — when those are not enough — a corticosteroid injection to calm swelling around the nerve. Our carpal tunnel vs tendonitis guide covers how the condition is told apart from look-alikes.

Hydrodissection takes a different route. Working under ultrasound guidance, a clinician injects fluid around the median nerve to gently separate it from the tissue it may be sticking to, with the aim of letting the nerve glide more freely. The fluid can be saline, a dextrose solution, or saline mixed with a steroid. The open question — the one 2026 research finally tested head-on — is whether the steroid is doing the work, or whether the fluid separation itself is.

The October 2026 Radiology trial

Researchers in India ran a prospective randomized controlled trial in people whose carpal tunnel syndrome had not responded to conventional treatment — pain medication, splints, lifestyle changes, and in some cases earlier steroid injections. Participants were split into three groups:

• Ultrasound-guided hydrodissection with normal saline alone
• Hydrodissection with saline plus a corticosteroid
• A conventional ultrasound-guided corticosteroid injection alone

Patients were scored on symptom, function, and pain questionnaires, and the median nerve was measured on ultrasound at four, 12, and 24 weeks. The pattern was consistent:

• All three groups felt better at four weeks. Early on, a steroid injection works — nobody disputes that.
• Only the hydrodissection groups kept improving. At 12 weeks and at six months, both saline groups continued to gain, while the steroid-only group's symptoms had returned toward where they started.
• Adding the steroid added nothing long-term. Saline-plus-steroid and saline-alone performed about the same at 24 weeks — a notable result, because steroids carry known local risks such as skin changes, fat thinning, and tendon weakening, which the study's authors flagged.
• The nerve itself looked less swollen. Per the Radiological Society of North America summary of the study, the median nerve's cross-sectional area shrank by roughly 43–45% after hydrodissection, versus about 15% after steroid injection alone.
• The procedure was brief and, in this trial, uneventful. It averaged about 15 minutes, needed no anesthesia or hospital stay, patients returned to work within about an hour, and no significant complications were observed.

Hold the enthusiasm to scale, though. This was a single-center trial with a modest number of participants, in patients with refractory symptoms, followed for six months — not years. The authors themselves call for larger multicenter studies with longer follow-up, and they have already launched a follow-up trial comparing different fluids, including dextrose versus saline.

The second 2026 trial: dextrose vs steroid

The Radiology result did not arrive alone. In May 2026, Muscle & Nerve published a randomized, double-blind trial from Slovenia with a clever design: 57 patients with carpal tunnel syndrome in both hands (114 hands in total) had one hand treated with 5% dextrose in water and the other with a corticosteroid, each patient serving as their own comparison. Everyone was followed for 12 months.

The headline: both fluids produced similar improvement. The strongest relief came in the first three months. About half of hands in each group had a clinically meaningful improvement in symptom scores at one and three months; by 12 months that share had fallen to 29% for dextrose and 25% for steroid. The authors concluded that dextrose is a reasonable non-steroidal alternative for this kind of injection therapy.

Read together, the two trials point the same way, with an honest caveat attached. Steroid-free options held up as well as — in the Radiology trial, longer than — the steroid standard. But benefits faded for many patients over a year in the dextrose trial, and neither study says anything about people with severe nerve damage, constant numbness, or muscle wasting. Those are surgical conversations, not injection ones.

What these results do not change

• First-line care is still first-line. Both trials enrolled people already diagnosed by clinicians. Night splinting — see our guide to the best wrist braces — activity changes, and fixing your workstation remain the starting point, not a footnote.
• Ergonomics still carry the daily load. An injection does not fix a desk that bends your wrist upward eight hours a day. Run the desk ergonomics checklist and keep up the wrist stretches regardless of what happens in a clinic.
• Diagnosis still comes before treatment. Thumb arthritis, tendon problems, and neck issues can mimic carpal tunnel syndrome. Ultrasound-guided procedures assume someone has confirmed which structure is actually the problem.
• Availability varies. Hydrodissection is a technique, not a product. Whether a clinician near you offers it, and whether insurance covers it, are local questions with no universal 2026 answer.

Questions worth asking a clinician

• Has my diagnosis been confirmed — for example with nerve conduction testing or ultrasound — or are we treating a suspicion?
• Which conservative steps have I genuinely completed, and for how long?
• If an injection is on the table, is it a steroid injection, a perineural injection, or hydrodissection — and what fluid?
• What improvement should I expect at three months, and what is the plan if symptoms return by month twelve — as they did for many patients in the 2026 dextrose trial?
• At what point would you refer me to a hand surgeon instead?

Sources

• Bose, Tandon et al., "Efficacy of US-guided Hydrodissection for Carpal Tunnel Syndrome: A Prospective Randomized Controlled Trial," Radiology (published online October 6, 2026), summarized by the Radiological Society of North America: MedicalXpress, October 6, 2026.
• Omejec et al., "Efficacy of Perineural Dextrose Versus Corticosteroid Injection for Carpal Tunnel Syndrome: A Randomized, Double-Blind Clinical Trial," Muscle & Nerve (first published May 28, 2026): Wiley Online Library.

Data checked October 15, 2026. Both trials were small and single-country; treat their findings as promising early evidence, not settled practice.